ISSN 1662-4009 (online)

ey0017.3-13 | Clinical trials for thyroid disease | ESPEYB17

3.13. Cognitive function in children with idiopathic subclinical hypothyroidism: Effects of 2 years of levothyroxine therapy

D Capalbo , S Alfano , M Polizzi , R Di Mase , N Improda , A Esposito , C Bravaccio , M Salerno

To read the full abstract: J Clin Endocrinol Metab. 2020;105:e774–e7781.This prospective non-randomized clinical trial investigated the effect of two-years levothyroxine treatment in children with subclinical hypothyroidism (TSH 5.0–9.9 mU/l with normal FT4 for two years preceding the study) starting at a mean age of 9 years. Capalbo et al. observed no change in IQ scores in 20 children after two-years of levothyroxine. Furthe...

ey0020.1-6 | Congenital Hypothyroidism | ESPEYB20

1.6. Effect of initial levothyroxine dose on neurodevelopmental and growth outcomes in children with congenital hypothyroidism

A Esposito , MC Vigone , M Polizzi , MG Wasniewska , A Cassio , A Mussa , R Gastaldi , R Di Mase , G Vincenzi , C Pozzi , E Peroni , C Bravaccio , D Capalbo , D Bruzzese , M Salerno

Brief summary: Current guidelines for congenital hypothyroidism recommend a starting dose of 10–15 μg/d of levothyroxine for optimal treatment (1). Over the last years, some studies suggested that overtreatment of patients during infancy by high levothyroxine doses might have negative effects on neurocognitive and behavioral development (2). The presented multicenter prospective randomized trial aimed at comparing the effect of higher (12.5–15.0 μg/d levoth...

ey0019.5-1 | Novel treatments for rare skeletal disorders | ESPEYB19

5.1. Targeting TGF-β for treatment of osteogenesis imperfecta

IW Song , SC Nagamani , D Nguyen , I Grafe , VR Sutton , FH Gannon , E Munivez , MM Jiang , A Tran , M Wallace , P Esposito , S Musaad , E Strudthoff , S McGuire , M Thornton , V Shenava , S Rosenfeld , S Huang , R Shypailo , E Orwoll , B Lee

J Clin Invest. 2022 Apr 1;132(7):e152571. doi: 10.1172/JCI152571.Abstract: https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/35113812/In brief: Currently, there is no disease-specific therapy for osteogenesis imperfecta (OI) where most children, of all forms of OI, with significant fracture history, are managed by bisphosphonates...